induction and the maintenance of remission in children and adolescents with inflammatory bowel disease (IBD) refractory to standard therapies including anti-tumor necrosis factor alpha biologics. 7 However, thalidomide use is often limited by its safety profile. The risk of teratogenicity, which led to the bad reputation of thalidomide since the epidemic of phocomelia in the sixties, is nowadays controlled with strict pregnancy prevention programs that regulate the dispensation of the drug. Peripheral neuropathy is one of the most frequent adverse events complained and is a common cause of treatment discontinuation. Thalidomide-induced peripheral neuropathy (TiPN) is an axonal, length-dependent, predominantly sensory polyneuropathy and is reported to be reversible in most patients after drug suspension. [8] [9] [10] [11] [12] [13] Cumulative dose has been proposed as the major risk factor for TiPN development, but variants in genes involved in inflammation and peripheral nervous system repair have been recently implicated. 8 However, information on TiPN mostly derives from studies on adults with multiple myeloma, and little is known about the risk factors and the course of TiPN particularly in patients with IBD. 14 We have previously reported the efficacy of thalidomide in inducing and maintaining clinical remission in children with Crohn's disease and ulcerative colitis. 5, 6 The aim of this study was to investigate the factors predisposing to the development of TiPN and to evaluate the course of the disorder.
METHODS
We performed a retrospective cohort study that involved 5 tertiary pediatric gastroenterology centers in Italy and that was conducted from September 1, 2015, to March 31, 2016. These centers previously formed a pediatric research network (Italian Thalidomide Study Group), shared their clinical experience, and developed a common clinical practice for the use of thalidomide in pediatric IBD.
Patients aged ,18 years with a diagnosis of Crohn's disease, ulcerative colitis, or indeterminate colitis (nowadays defined as IBD unclassified) 15 were identified within the electronic databases of the participating centers. All patients treated with thalidomide at any course of their disease between January 1, 1998, and March 31, 2016, were considered eligible for the study. Thalidomide was given off label in cases of refractory IBD with the parents' consent and after the acceptance of the risk management programs provided by the drug's manufacturer.
A baseline clinical and neurophysiological assessment was required before starting thalidomide. Patients with pre-existing peripheral neuropathy were not eligible to take the drug. For inclusion, patients treated with thalidomide had to be followed with a regular 3-month neurologic follow-up including nerve conduction studies performed by a neurologist according to a shared clinical protocol adopted for the use of thalidomide by the Italian Thalidomide Study Group to ensure the patient's safety; the cost of the neurophysiological studies was supported by the Italian National Health System. During treatment, patients were asked about subjective neurologic abnormalities, and a neurologic examination was performed at each visit. Impact of symptoms on daily life was classified according to the United States National Cancer Institute Common Toxicity Criteria (version 4.0, 2009) for sensory and motor neuropathy.
Nerve conduction studies were performed with conventional methods and surface recording and included the examination of the sensory nerve conduction in median, ulnar, peroneal, and sural nerves and the motor-nerve conduction velocity in median, ulnar, and external popliteal nerves. The results of the examination were compared with reference values of the agerelated pediatric scale adopted in each center.
A reduction in the value of the sensory nerve action potential amplitude of the sensory nerves and/or of the compound muscle action potential of the motor nerves below minus 2 SD of the reference, with the relative preservation of the sensory conduction velocity and/or muscle conduction velocity, was taken as the minimum requirement for the definition of an electrophysiological sensory, motor, or sensorimotor axonal neuropathy according to previous studies. 16 Clinical peripheral neuropathy was defined by the presence of clinical symptoms or signs of peripheral nervous system impairment and pathologic neurophysiological alterations. Patients with symptoms or signs without concomitant or subsequent electrophysiological neurological alterations were considered as cases of clinical TiPN to reduce any underreporting bias.
In case of exclusive alteration of the nerve conduction studies without any clinical disturbances, the definition of subclinical peripheral neuropathy was adopted.
Thalidomide was administered at the dose of 1.5 to 2.5 mg$kg 21 $d 21 at bedtime and could be initially associated with a course of steroids. The decision of changing the dose or drug discontinuation because of peripheral neuropathy was taken by the pediatric gastroenterologist with consultation of the neurologist, according to the degree of neurologic alterations and to IBD activity.
During follow-up, clinical recovery from peripheral neuropathy was defined as resolution of symptoms and signs. Data were collected until the latest available follow-up for all patients including those who had already stopped thalidomide.
Neurophysiological alterations were considered recovered in case of normalization of the parameters at the last instrumental follow-up.
To identify potential risk factors for TiPN development, we compared characteristics of patients who developed clinical or subclinical neurologic disturbances with those who did not. Information acquired for this study included demographic features, type of IBD, disease distribution according to the Paris classification, 17 immunosuppressive or immunomodulatory therapies preceding thalidomide treatment, use of metronidazole or calcineurin inhibitors (cyclosporine A, tacrolimus), which are possibly associated with peripheral neuropathy, 18, 19 previous or during thalidomide, and clinical response to thalidomide.
Modifications of thalidomide dose were analyzed to evaluate any possible influence on peripheral neuropathy course. All clinical data were extracted from paper and electronic charts.
To identify genetic biomarkers to predict TiPN occurrence,
, and SLC12A6 [rs7164902]) previously associated with TiPN in a study on patients with myeloma 8 were studied. Moreover, the contribution of the most relevant variant in CYP2C19 enzyme involved in thalidomide pharmacokinetics, which may influence thalidomide conversion to an active metabolite, was evaluated.
DNA was extracted from peripheral blood using a commercial kit (Sigma Aldrich, Saint Louis, MO) and quantified using a NanoDrop Spectrophotometer (NanoDrop product, Wilmington, DE). Genotyping of variants was performed by TaqMan assays (Thermoscientific, Waltham, MA).
STATISTICAL METHODS
Categorical variables are presented as absolute numbers and percentages. Continuous variables are reported as median and interquartile range (IQR).
Variables associated with neuropathy and with outcomes of neuropathy were analyzed using logistic regression. The exploratory evaluation of association of candidate variants with neuropathy considered dominant genetic models given the low number of patients homozygous for variant alleles. All variants were tested for deviations from Hardy-Weinberg equilibrium.
The neuropathy-free survival was evaluated using Kaplan-Meier method. To evaluate the independent effect of variables associated with neuropathy and time to neuropathy, multivariate logistic regression and multivariate Cox regression were performed. Results of logistic regression are presented as odds ratio and 95% confidence interval (95% CI), whereas results of Cox regression are presented as adjusted hazard ratio (aHR) and 95% CI. All statistical tests were 2-sided. A P value , 0.05 was considered as statistically significant. The analysis was performed using Stata 12.
ETHICAL CONSIDERATIONS
Part of the patients included in this study were enrolled within the 2 randomized controlled trials and gave the informed consent to the use of all their clinical data as detailed elsewhere. 5, 6 The remainder of patients gave informed consent for the use of their clinical data with a generic research consent form; a specific consent for this study was not required by the ethical committees given its retrospective nature.
Genetic studies were conducted from blood samples of patients prospectively collected with informed consent of the parents or legal guardians and stored up within the biologic bank of the IRCCS Burlo Garofolo.
The study was approved by the independent ethical committee of the coordinating center.
RESULTS
One hundred fifty-two patients were identified: 10 patients were excluded because of drug withdrawal before any neurologic assessment, whereas 142 patients met the inclusion criteria. Baseline characteristics of the patients treated with thalidomide are shown in Table 1 .
TiPN was found in 103 (72.5%) patients: clinical (symptoms, sings, or both) and instrumental features of TiPN were reported in 55 (38.7%) patients; subclinical neuropathy was reported in 38 (26.8%) patients; 10 (7.0%) patients complained of peripheral neurologic disturbances (cramps or paresthesias) without concomitant or subsequent physical or electrophysiological neurological alterations. In patients with clinical and instrumental TiPN, alterations in the nerve conduction studies appeared first in 27 (49.1%) patients, were contemporary to the clinical anomalies in 20 (36.4%) patients, whereas they were subsequent in 8 (14.5%) patients.
Characteristics of the patients according to the type of TiPN are reported in Table 1 , Supplemental Digital Content 1, http:// links.lww.com/IBD/B550. Characteristics of the instrumental and clinical neuropathy are reported in Table 2 . All motor and sensory symptoms were classified as grade 1 as none interfered with daily activities.
Median neuropathy-free time of treatment was 16.5 months (IQR 10.1-38.4). Probability of TiPN-free time was 70.0% and 35.6% at 12 and 24 months of treatment, respectively (Fig. 1) .
One hundred ten (77.5%) patients had stopped thalidomide at the study retrieval date: clinical or subclinical neuropathy was the cause of the treatment withdrawal in 46 (41.8%) patients. (see Fig. 1 However, to take into account the different length of follow-up between patients, we calculated the mean daily dose (milligram and milligram per kilogram). The risk of TiPN increased depending both on daily dose (odds ratio 1.03, 95% CI, 1.02-1.05, P , 0.001) and on daily dose per kilogram of patient's body weight (odds ratio 7.71, 95% CI, 3.36-17.67) (Fig. 2) .
Kaplan-Meier analysis showed different survival probability at different daily doses as showed in Figure 3 ( For the genetic analyses, DNA was extracted from blood samples of 87 patients (47 with neuropathy). Variants in ICAM1 and SERPINB2 genes were found to be less frequent in children who developed neuropathy, according to the dominant model (3.8% versus 20.7%, P ¼ 0.022 and 31.5% versus 56.2%, P ¼ 0.04, respectively). Frequencies of wild type and mutated ABCA1, PPARD, SLC12A6, and CY2C19 genes were similar between patients with and without peripheral neuropathy (Table 3 ). Cox regression model confirmed that higher mean daily doses were independently associated with an increased risk of TiPN, whereas polymorphisms in ICAM1 were independently associated with a decreasing risk (see Table 2 , Supplemental Digital Content 3, http://links.lww.com/IBD/B552).
Focusing on the outcome of TiPN, we did not identify any patient or disease characteristic that influenced the course of the neurologic disturbances. Median daily doses and cumulative doses at the end of the treatment were found to be similar between patients whose symptoms and nerve conduction studies alterations resolved and patients with persistent TiPN (median 63. Intriguingly, although not statistically significant, 2 of 2 (100%) patients with polymorphisms in ICAM1 resolved the anomalies in the nerve conduction studies compared with 18/40 (45%) patients with the wild-type gene (P 0.22).
As patients who presented exclusively symptoms without instrumental signs of neurological alterations may represent atypical cases of TiPN, we performed a sensitivity analysis considering those patients in the no-TiPN group, and the results did not change significantly.
DISCUSSION
Our study represents the largest experience on safety of thalidomide in children and young adults with refractory IBD. In our cohort, 72.5% of patients developed clinical or electrophysiological alterations suggestive of axonal, sensory, or sensorimotor peripheral neuropathy. We found that the main variables that influenced the onset of TiPN were the mean daily dose and genetic variations in genes involved in the inflammation and the repair of the peripheral nervous system. No risk factor related to IBD characteristics resulted as significantly involved. Symptoms of TiPN were generally transient and resolved in more than 90% of patients, also before thalidomide withdrawal, whereas in almost half of patients, nerve conduction studies anomalies persisted for months after the drug withdrawal.
The frequency of TiPN in our cohort is consistent to that reported in previous smaller studies in children 7 and adults 12, 20 with Crohn's disease even when subclinical alterations were included in the definition of TiPN. 13, 14, 21 We performed a regular nerve conduction monitoring as a prudential practice to detect neurological disturbances in a subclinical phase and to modulate the dose of thalidomide in the hypothesis that dose reduction will prevent TiPN worsening. However, the need for nerve conduction studies in the absence of symptoms has been questioned because of a poor correlation between the extent of the neurophysiological anomalies and the presence and severity of symptoms. 10, 13, 21, 22 Moreover, some patients may have exclusive neurologic symptoms secondary to a small fiber neuropathy not detectable by ordinary nerve conduction studies. 9 Regarding risk factors, we showed that the association between thalidomide and metronidazole, an antibiotic often used in the treatment of IBD which is a known cause of axonal peripheral neuropathy, 11 did not increase the risk of TiPN.
So far, studies that analyzed the influence of thalidomide dose led to discrepant results. In adult patients with oncologic and dermatologic diseases treated with doses of thalidomide up to 1200 mg/d, higher cumulative doses were associated with an increased risk of symptoms, signs and electrophysiological disturbances and a lower probability of resolution. 22, 23 In children, Priolo and colleagues observed a higher incidence of TiPN when cumulative doses were .20 g and when duration of therapy was . 20 months, 24 whereas Liew and colleagues reported the onset of TiPN with cumulative doses . 60 g. 14 On the other hand, a study in children with refractory Crohn's disease showed no difference between cumulative doses in patients who developed TiPN and in patients who did not. 7 Thalidomide metabolism is mainly due to spontaneous hydrolysis, whereas a small quantity of the drug is biotransformed in the liver by the cytochrome p450 (CYP), in particular by the CYP2C19 isoform. In our study, genetic variations of CYP2C19 were not associated with a different risk of TiPN, consistently with previous reports. 8 On the contrary, similarly to a previous study in patients with multiple myeloma, 8 we found that polymorphisms in ICAM1 and SERPINB2 reduced the risk of neuronal damage and favored TiPN resolution, supporting the hypothesis that genetic susceptibility may have a significant contribution in the natural history of TiPN.
The gene ICAM1 encodes for an intercellular adhesion molecule that is known to play a key role in inflammatory processes by facilitating leukocyte endothelial transmigration and directly transducing proinflammatory signals. 25 It has been shown that ICAM1 is involved in nerve repair after traumatic injury. 26 SER-PINB2 is a serine protease inhibitor whose levels increase during cellular stress with cytoprotective effects in neurons. 27, 28 Although inflammation has not been reported as a typical histological feature in nerve biopsies of patients with TiPN, 22 the reduced expression of proinflammatory genes has been already reported as a neuroprotective factor. 28 The study has some limitations. First, its retrospective design did not allow us to completely evaluate the effect of different strategies of dose management. Most patients lowered thalidomide dose during treatment and resolved their neurological symptoms, but the period and the number of dose reductions did not consistently affect the course of the instrumental signs of TiPN. Anyway, we cannot completely exclude that continuing the original dose after the onset of neurologic disturbances could worsen the TiPN outcome. Thus, because maintenance of longterm remission is not affected, 5, 6 reduction of thalidomide dose after IBD remission that has been achieved could be considered a prudent strategy not only to delay the onset of TiPN but also to prevent its evolution.
A second limitation is that the length of our instrumental follow-up after thalidomide withdrawal was limited. Even if most symptoms and signs were transient, later neurologic evaluations are needed to understand the long-term history of TiPN and to evaluate whether there is an increased risk of neuropathy in adulthood. None of our patients developed new neuronal symptoms after thalidomide stop, and the possibility of a "coasting phenomena" (the worsening of symptoms of neuropathy after treatment has been ceased) 10 seems unlikely in children.
A third limitation is that genetic tests were performed only in a subset of patients and deal with relatively small numbers. However, this is the first study that analyzed the influence of polymorphisms in predisposing to TiPN in children with IBD. Finally, the findings of our study regard children with IBD and Despite these limitations our study have the strength to report a detailed description of the clinical and genetic risk factors and the natural history of TiPN and to be based on the largest cohort of patients with IBD treated with thalidomide.
In conclusion, a high proportion of children with IBD treated with thalidomide experienced clinical or instrumental signs of peripheral neuropathy. Symptoms were generally mild and resolved soon after drug discontinuation. Although genetic predisposition may play a significant role in TiPN occurrence, it is possible that the risk of TiPN could be reduced by de-escalating thalidomide dose after remission is achieved. The same strategy may be useful in limiting TiPN progression.
Further studies are needed to elucidate the biologic mechanism of TiPN and to define the strategies of therapy personalization to reduce the risk of TiPN and to favor its resolution.
